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Cellular expression of the herpes simplex virus type 1 thymidine kinase (HSV1-TK) gene promotes cell death in the 
presence of specific nucleoside analog substrates such as acyclovir (ACV). We have reported that lymphoid CD4 + cells 
harboring an HSVl-TK gene, under the transcriptional control of the HIV-1 long terminal repeat (HUT-TK), are completely 
protected from HIV-1 spread in the presence of 10/~M ACV. In this report we clarify the efficiency, generality, and mechanism 
of this protective effect. We show that the protection from HIV-1 spread in HUT-TK cells obtains from both an inhibition of 
HIV reverse transcription by ACV metabolites and an HIV-induced and ACV-dependent cell killing. We also demonstrate 
that monocytic ells harboring the HIV-l-inducible HSVl-TK gene are protected from HIV spread in the presence of ACV. 
These observations facilitate the design of therapeutic strategies to limit HIV replication based on HSVl-TK expression. 
© 1995 Academic Press, Inc. 
INTRODUCTION 
Effective treatment of HIV-1 infection will require re- 
duction of the viral burden in the patient and restoration 
of a functional immune system and its protection from 
subsequent reinfection and depletion. Gene therapy ap- 
proaches for AIDS seek to repepulate an HIV-infected 
individual with genetically modified hematopoietic stem 
cells, which will give rise to mature cells resistant to HIV 
replication or spread. 
Several anti-HIV gene therapy approaches have been 
evaluated in vitro for their ability to protect susceptible 
cells from HIV infection (Malim et al., 1989; Trono et al., 
1989; Buonocore and Rose, 1990; Sarver et al., 1990; 
Sullenger et aL, 1990; Sczakiel and Pawlita, 1991). De- 
spite their efficacy in cell culture systems, uncertainties 
remain regarding the ultimate therapeutic benefit of 
these various strategies, and effects upon the various 
lineage's of transduced cells in the host remain to be 
determined. For example, retroviral delivery of TAR RNA 
decoys (Sullenger et al., 1990) may lead to interference 
with the normal function of cellular TAR-binding proteins. 
Strategies based upon intracellular immunization with 
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viral transdominant mutant proteins may unmask toxic 
interactions with host proteins. Transdominant mutants 
of Gag, for example, interfere with assembly and release 
of infectious viral particles (Trono et al., 1989) but may 
also interfere with normal cellular function of cyclophilin 
A, to which it may still bind (Luban eta/. ,  1993). Similarly, 
the potential exists for interaction of transdominant Rev 
mutants with host cell factors in the hematopoietic lin- 
eage (Malim et al., 1989). Ribozymes that cleave HIV-1- 
specific RNAs require an ordered secondary structure 
for their activity, and double-stranded RNA structures are 
among the most potent inducers of toxic interferon re- 
sponses. 
All of these therapeutic interventions seek to interfere 
with HIV replication after proviral integration and result 
in the generation of latently infected cells harboring an 
infectious provirus. The persistence of these cells, rather 
than their ablation, leaves open the possibility for later 
induction of viral production and reemergence of dis- 
ease. Finally, none of the above strategies have a prece- 
dent in antimicrobial therapy. It would be useful if a gene 
therapy strategy could exploit an existing knowledge 
base on therapeutics. 
We reasoned that it might be more effective to sacrifice 
HIV-infected cells and thus abort, rather than interfere 
with, viral replication. We developed an experimental sys- 
tem in which HIV replication triggers the destruction of 
a genetically modified host cell by placing a conditional 
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toxin under the transcriptional control of HIV regulatory 
sequences. In the absence of the viral-encoded Tat pro- 
tein, this toxin is expressed at a basal low level, and its 
expression is strongly stimulated by Tat expression dur- 
ing HIV replication. Because of the basal expression in 
noninfected cells, a suicide mechanism with a dose-de- 
pendent effect is necessary (Caruso etaL, 1992). Further- 
more, with the prospect of an in vivo use, a conditional 
toxicity that requires the administration of an exogenous 
molecule is preferable. We used the herpes simplex virus 
type 1 thymidine kinase (HSVl-TK), that efficiently phos- 
phorylates nucleoside analogs such as acyclovir (ACV) 
into monophosphorylated molecules (Fyfe et aL, 1978; 
Elion, 1983). These are converted into nucleoside tri- 
phosphates that interfere with cellular DNA synthesis by 
either competitive inhibition with natural nucleotides or 
incorporation and chain termination and eventually lead 
to cell death (Nishiyama and Rapp, 1979; Furman et aL, 
1980; Davidson et al., 1981). HSVl-TK is therefore a con- 
ditional toxin which converts a nontoxic nucleoside into 
a toxic nucleotide. The vast pharmacological and clinical 
experience with nucleoside analogs may facilitate rapid 
development of therapies based upon these compounds. 
We reported that lymphoid CD4 + cells harboring an 
HSVl-TK gene under the control of a truncated HIV-1 
long terminal repeat (LTR) were completely protected 
from HIV spread when grown in the presence of 10 ffM 
ACV, a concentration well tolerated by uninfected cells 
(Caruso and Klatzmann, 1992). These experiments did 
not distinguish whether this effect was due to the de- 
struction of the initial population of infected cells orto an 
inhibition of HIV reverse transcription by phosphorylated 
ACV. ACV-triphosphate (ACV-TP) inhibits HIV reverse 
transcription, but at least 20-fold less potently than zido- 
vudine (AZT)-TP (Cheng eta/., 1987). 
In this paper, we further explore the efficiency and 
mechanism of action of this inhibition of HIV spread. We 
show that the overall protection from HIV spread involves 
not only an HIV-induced AOV-dependent cell suicide, but 
also the inhibition of HIV reverse transcription by ACV 
metabolites. 
MATERIALS AND METHODS 
RNase protection assay (RPA) 
RPA was performed as described elsewhere (Salomon 
et aL, 1994). 
and the cells were washed twice with phosphate-buf- 
fered saline. Metabolites were extracted overnight with 
0.5 ml of 60% methanol at -20  °. After centrifugation to 
remove cell debris, the supernatant was removed under 
reduced pressure and the dried extracts were resus- 
pended in 500 #1 of deionized water and filtered through 
a 0.22-ffm filter. Two hundred microliters of samples was 
assayed by fast protein liquid chromatography (Phar- 
macia-LKB Instruments, Uppsala, Sweden) on the poly- 
mer-based monoQ HR 5/5 strong anion-exchange col- 
umn and eluted with ammonium phosphate buffer (pH 
7.0) using an improved gradient program in the concen- 
tration range 0.02-0.5 M (Kremmer etaL, 1989). Radioac- 
tivity was counted at the column exit with the Radiomatic 
FIo-one Beta A-500 (Packard, Camberra) and peaks were 
analyzed with the FIo-one/Data Software. 
Cell culture, plasmid, and transfection 
HUT-78, U937, and their derivative cells were cultured 
in RPMI medium (Fiobio, France) supplemented with 10% 
fetal calf serum (Labsystems France). ~-CRIP ampho- 
tropic packaging cells (Danos and Mulligan, 1988) were 
cultured in Dulbecco's modified Eagle's medium (GIBCO) 
containing 10% newborn calf serum (HyCIone). pLTR-TK, 
a plasmid encoding an HIV-inducible HSV1-TK gene, and 
HUT-TK cells have been previously described (Caruso 
and Klatzmann, 1992). HUT-TKMLv cells have been gener- 
ated after infection of HUT-78 cells and selection with 
G418 (1 mg/ml). The retroviral supernatant used was har- 
vested 48 hr after transient transfection of '~-CRIP cells 
with pLITK, a retroviral vector constructed by cloning of 
the 1130-bp coding sequence of HSVl-TK in the BamHI 
site of pLJ (Korman et aL, 1987). 
U-TK clones were generated from U937 cells as fol- 
lows. U937 cells (3 x 107 ) were rinsed with ice-cold 
phosphate-buffered saline, pelleted by centrifugation, 
rinsed again, and then resuspended in 0.4 mf RPMI me- 
dium. They were kept on ice for 10 min and the cell 
suspension was added to a prechilted electroporation 
cuvette together with 20 fig pLTR-TK. An electric pulse 
(0.25 kV, 1800 5F) was delivered to the cells using a Bio- 
Rad electroporator. Cells were resuspended in 50 ml of 
culture medium and distributed in the 48 wells of a 
multiwell plate (Costar). After 48 hr 500 #g/ml of hygro- 
mycin was added. Half of the volume of the medium was 
removed every 3-4 days and cells were cultured in the 
selection medium until clones appeared. 
Nucleotide analysis by fast protein liquid 
chromatography 
Cell extracts were prepared as followed. Cells (2 x 
107 ) were incubated for 7 hr with 0.54 #M [SH]ACV (22 
Ci/mmol) from Moravek Biochemicals (Brea, CA) in a final 
volume of 5 ml medium. The medium was then removed 
Virus and viral infection procedures 
U937, U-TK cells (106) and HUT-78, HUT-TK, and HUT- 
TKML v cells (2 × 10 s) were infected in a 100-#1 final vol- 
ume for 3 hr at 37 ° with 100 tissue culture infectious 
doses of the HIV-l~ai strain. The cells were then washed 
once and resuspended in medium with different ACV 
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concentrations. Every 2 or 3 days, half of the cells were 
discarded, a sample of supernatant was withdrawn for 
the analysis of viral antigens, and fresh medium was 
added. For the detection of HIV-1 antigens we used the 
ELAVIA Agl Kit (Diagnostics Pasteur, Marnes la Co- 
quette, France). 'For the transactivation analysis, 107 HUT- 
TK cells were infected with 2 x 106 tissue culture infec- 
tious doses for 6 hr at 37 ° . Cells were then washed and 
cultured for another 22 hr. At that time total RNA was 
extracted for RPA. 
Colorimetric tetrazolium salt M'i-I {3-(4,5- 
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide} 
assay 
HUT-78, HUT-TK, and HUT-TKc~ ceils (2 X 10 ~) were 
cultured in a 24-well plate (Costar) with or without 10 #M 
ACV for 15 days. Every 3 or 4 days cell viability was ana- 
lyzed by incubation of 100 #1 of cell suspension with 10 
#1 of Mq-i- solution (5 mg/ml in phosphate-buffered saline) 
for 5 hr at 37 ° . HCI (150 #1, 0.04 N) in isopropanol was 
added and mixed thoroughly to dissolve the dark blue 
crystals. After few minutes at room temperature the plates 
were read at 550 nm wavelength (Mosmann, 1983). 
Evaluation of HIV DNA synthesis 
The effect of ACV on HIV DNA synthesis in infected 
HUT-78 or HUT-TK cells was evaluated using a previously 
described cocultivation method (Li and Burrel, 1992; Sato 
etal., 1992; Barbosa eta/., 1994). Briefly, 2 X 106 chroni- 
cally HIV-ljai-infected H9 cells, producing an average of 
200 ng of HIV-1 p24/ml, were added to 8 X 106 HUT-78 
or HUT-TK cells that had been pretreated for 3 hr with 
either 10 #M ACV or 5 #M AZT (Wellcome), or left un- 
treated, in a total volume of 10 ml. Coculture was carried 
out for 6 hr, at which time extensive cytopathic effect had 
developed comparably in all six cultures. Low-molecular- 
weight DNA was then extracted from the cocultivated cells 
using the method of Hirt (Hirt, 1967). Viral DNA was ana- 
lyzed by agarose gel electrophoresis of the amount of 
extracted DNA corresponding to 3.3 X 106 cells, followed 
by Southern hybridization with a 1.8-kb HIV-1 32p-labeled 
probe from the pol region. Quantitative analysis of the 
amounts of HIV-1 viral DNA was subsequently performed 
on a phosphorimager (Molecular Dynamics), where only 
the 9.7-kb HIV-1 DNA species corresponding to full-length 
unintegrated linear genomes was taken into account. 
RESULTS 
Basal and transactivated transcription of HSV1-TK in 
HUT-TK cells 
Our therapeutical strategy requires a controlled regu- 
lation of HSV1-TK expression. Since an internal promoter 
within the HSV1-TK coding region has been described 
(Roberts and Axel, 1982; AI-Shawi et al., 1991), we ana- 
lyzed basal and HIV-transactivated HSV1-TK mRNA ex- 
pression and mapped the transcript initiation site. We 
used an RNAse protection assay with a RNA probe that 
extends beyond the HIV-LTR start site (Fig. 1A). The HUT- 
TK cell line contains an HSV1-TK gene under the control 
of HIV regulatory sequences, and its derivation has been 
previously described (Caruso and Klatzmann, 1992). RNA 
was extracted from uninfected HUT-TK cells and 28 hr 
after a high multiplicity of infection (m.o.i.). Basal HSV1- 
TK expression can be detected in uninfected HUT-TK 
cells. The major protected band corresponds to tran- 
scripts initiated at the. H IV-LTR start site (Fig, 1B). A minor 
shorter band is frequently detected, 80 bases shorter 
than full-size transcripts. This band is distinct from the 
even shorter HSV1-TK transcripts that initiate from the 
internal promoter in the HSV1-TK coding sequence (Rob- 
erts and Axel, 1982; AI-Shawi et al., 1991). The intensity 
of this band varies with experimental conditions of the 
protection assay. It might correspond to single-strand 
RNA digestion in the 5' R region of the transcripts, due 
to the formation of a secondary structure during hybrid- 
ization or to a partial denaturation during RNase diges- 
tion. Indeed, the R region sequence has a much lower 
guanine-cytosine content compared to the 65% gua- 
nine-cytosine content of the HSV1-TK gene. 
In acutely HIV-infected cells, approximately 10% of the 
cells are infected at the time of RNA extraction (Caruso 
and Klatzmann, 1992), and there is an overall 10-fold 
increase in HSV1-TK transcripts levels that are correctly 
initiated at the HIV-LTR start site. This suggests up to 
100-fold increase in mRNA accumulation in individual 
infected cells. We have not detected in these experi- 
ments any expression of truncated transcripts initiated 
within HSV1-TK. These data indicate that HSV1-TK ex- 
Ibression is controlled by the HIV regulatory sequences 
in HUT-TK cells. 
Comparison of HSV1-TK expression, ACV-induced cell 
death, and ACV metabolites in uninfected and 
chronically HIV-infected HUT-TK cells 
The cellular toxicity of ACV in HSV1-TK-expressing 
cells is dependent upon both the concentration of nucle- 
oside analogs and the level of expression of the enzyme 
(Borrelli etaL, 1988). We have previously shown that ACV 
is well tolerated by HUT-TK cells which express HSVl- 
TK (Caruso and Klatzmann, 1992). To demonstrate that 
increased HSV1-TK expression during HIV infection 
would lead to ACV-induced cell death, we needed a ho- 
mogeneous population of infected cells. We used a popu- 
lation of chronically infected HUT-TK (HUT-TKcj) cells that 
emerged after HIV infection of HUT-TK cells in the ab- 
sence of ACV. These cells secrete high amounts of infec- 
tious particles, and HSV1-TK transcript level is increased 
40-fold (data not shown). 
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FIG. 1. Transcriptional initiation and transactivation of the HSVl-TK gene. (A) HIV-1 LTR sequences are positioned to direct transcription of the 
HSV1-TK gene. The transcription initiation site is indicated (arrow), as are the positions of the initiation and stop codons for HSV1-TK. The structure 
of the antisense RNA probe, and of the expected fragment protected by HSV1-TK transcripts from RNAse digestion, are indicated below. (B) HSVl- 
TK transcripts of uninfected HUT-TK cells and 28 hr after HIVq infection at high m.o.i, were analyzed by RPA. 
Chronically infected HUT-TK cells have a doubling time 
twice that of parental uninfected cells. This is similar to 
the difference in growth rate of uninfected and chroni- 
cally infected HUT-78 cells and reflects the cytopathic 
effects of HIV. We tested the cell viability of parental 
HUT-78, HUT-TK, and HUT-TKc~ ceils cultured with 10 #M 
ACV, a dose that completely blocked HIV spread in HUT- 
TK cells. HUT-78 and HUT-TK cells were not affected by 
ACV treatment as measured with a Mqq- assay (Mos- 
mann, 1983), but there was a progressive death of HUT- 
TKc~ cells. After 4 days of treatment, the cell viability is 
reduced by almost 50% (Fig. 2A) and most cells are dead 
on Day 15. In repeated experiments in which more than 
107 HUT-TKc~ cells were grown in the presence of 10 #M 
ACV, we have never observed the emergence of resistant 
cells (data not shown). 
To demonstrate that the selective toxicity reflected al- 
tered ACV metabolism, we measured ACV phosphoryla- 
tien in HUT-78, HUT-TK, and HUT-TKc~ cells. Nucleotide 
pools were extracted from cells incubated with [3H]ACV 
for 7 hr, and the different AOV-phosphorylated forms 
were separated on anion-exchange columns by fast pro- 
tein liquid chromatography (Kremmer et aL, 1989). There 
was very low to undetectable ACV-TP amounts in paren- 
tal HUT-78 cells, a finding consistent with the low efficacy 
of cellular kinases to phosphorylate ACV (Ellen et aL, 
1977; Davidson et al., 1981). On the contrary, ACV-MP, 
ACV-DP, and ACV-TP are detected in HSVl-TK-express- 
ing cells. In HUT-TKc~ cells with 40-fold more HSVl-TK 
transcripts than H UT-TK cells, the ACV metabolite pattern 
is markedly shifted, with a fivefold increase in ACV-TP 
proportion compared to HUT-TK cells (Fig. 2B). 
ACV treatment of HIV-infected HUT-TK cells does not 
select a cell population with abnormal capacities to 
support HIV replication 
HUT-TK cells infected with HIV in the presence of 10 
#M ACV are completely protected from HIV spread (Ca- 
ruse and Klatzmann, 1992). It is possible that exposure 
to ACV selects a subpopulation of HIV resistant HUT-TK 
cells. To test this, ACV was discontinued 2 weeks after 
exposure to HIV, and the cells monitored for HIV replica- 
tion. No viral replication was detected for another 11 
days, at which time the cells were reinfected with HIV 
and split into two cultures, with or without 10 /~M ACV. 
HIV replication occurred in the untreated culture with 
kinetics identical to infection of the HIV naive HUT-TK 
cells. No HIV replication was detected in the presence 
of ACV (Fig. 3). Although some cells may persist with 
defective or latent genomes, they do not lead to a mea- 
surable reemergence of infectious virus after emoval of 
the drug. 
Monocytic cells harboring a Tat-inducible HSVl-TK 
gene are protected from HIV spread by ACV 
We generated U937 monocytic cells containing a Tat- 
inducible HSVl-TK gene, as previously described for 
HUT-TK cells. Six clones (U-TK) were analyzed for HSV1- 
TK mRNA expression by RPA. Three of the U-TK clones 
(U-TK9, 12, and 16) express correctly initiated HSV1-TK 
transcripts. The minor shorter band resulting 'from single- 
strand RNA digestion within R can also be observed. In 
one clone (U-TK8) the predominant HSVl-TK transcripts 
are initiated within HSVl-TK coding sequence. Two other 
clones did not express HSVl-TK (Fig. 4A). We estimated 
that U-TK12 and 16 clones expressed 5- to 10-fold less 
HSVl-TK transcripts than the HUT-TK clone, at a level of 
3-5 transcripts per cell, and even less for U-TK9. We 
tested the toxicity of ACV for these clones. While the 50% 
inhibiting concentration (IO5o) of ACV is 300 #M for HUT- 
78, up to 1 mM (the highest concentration that can be 
used in culture due to pH) had no detectable toxicity on 
U937 cells. The U-TK clones also showed a low sensitiv- 
ity to ACV with an IC~o of 1 mM, 100-fold higher than that 
for HUT-TK cells (data not shown). We next analyzed the 
protective effect of ACV against HIV infection. Parental 
HSV1-TK-MEDIATED BLOCK OF HIV-1 SPREAD 499 
A 
100. 
,ID , - . . . .  
._ 
> 
_= 5o.' ~;.~ 
o gtl  
4 8 12 15 
Days 
=- 
No ACV 
1 r ~  . ~  101~M ACV 
/,cv \ /' 
0 10 20 30 
Days 
B 
3O0OO 
E 
Q. 
O v 
._> 
~d 
O 
-O 
rr 
20000 
10000 
20000 
10000 
0 
20000 
10000 
HUT-78 
ACV 
0 
HUT-TK 
ACV 
ACV-MP A ACV'DP 
ACV 
HUT-TKc l  
10 20 30 40 50 60 
Retention time (min) 
FIG. 2. ACV-induced cell death and ACV metabolites in uninfected 
and chronically HIV-infected HUT-TK cells• (A) Effect of 10 #M ACV on 
HUT-78, HUT-TK, and HUT-TKcj cells viability. The three different cell 
types were cultured with 10 #M ACV and viability was assessed every 
3-4 days through Day 15 with the Mqq- assay. The viability is expressed 
in percentage of optical density of the cells cultured without drug. (B) 
Fast protein liquid chromatographic profiles of cellular extracts from 
HUT-78, HUT-TK and HUT-TKc~ cells incubated with [3H]ACV. A minute 
amount of ACV-TP was detected from HUT-78 cells• The percentage 
of ACV-MP, ACV-DP, and ACV-TP were, respectively, 21.1, 33, and 5.6% 
in HUT-TK cells and 15.1, 25.1, and 23.6% in HUT-TKa cells. 
FIG. 3. Protection and reinfection of HUT-TK cells• HUT-TK cells were 
infected by HIV and cultured with or without 10 ffM ACV. On Day 15, 
ACV treatment was discontinued for 10 days until a new challenge of 
HIV. At this time half of the cells were cultured with or without 10 
#M AOV. Every 3 -4  days, HIV antigens were measured in the culture 
supernatant by ELISA. 
U937 cells and U-TK clones were infected with HIV and 
cultured in the presence of various ACV concentrations. 
HIV replication in U937 cells was not affected by ACV. 
In contrast, there was a dose-dependent inhibition of HIV 
replication in U-TK cells. At 10 #M ACV, detection of 
HIV antigens was delayed by 3 days, compared to the 
untreated culture. At 30 #M ACV, HIV infection was 
completely inhibited during the 3-week culture period 
(Fig. 4B), 
Inhibition of reverse transcription contributes to the 
protection of HUT-TK cells by ACV from HIV spread 
ACV-TP is a weak inhibitor of HIV reverse transcriptase 
(Cheng et al., 1987). Since HUT-TK cells express suffi- 
cient basal levels of HSV1-TK to produce ACV-TP (Fig. 
2B), we measured the inhibition of HIV reverse transcrip- 
tion by ACV in these cells. HUT-TK and parental HUT-78 
cells were cocultured with chronically infected H9 cells 
in the presence of 10 #M ACV or 5 #M AZT or with 
no drug. Previous results have demonstrated that the 
chronically infected H9 cells do not have measurable 
unintegrated proviral DNA and that they very efficiently 
transfer infectious virus to uninfected cells (Barbosa et 
al., 1994). Six hours later Hirt DNA was extracted and 
analyzed by Southern blotting. AZT completely blocked 
the synthesis of HIV DNA in HUT-78 and in HUT-TK cells 
(Fig. 5). A partial decrease in proviral DNA accumulation 
occurred in HUT-78 cells in the presence of ACV, but 
was more pronounced in HUT-TK cells. Similar results 
were obtained in independent experiments using a semi- 
quantitative DNA PCR assay (data not shown). We con- 
clude that a component of the protective effect of ACV 
in this system derives from an inhibition of HIV reverse 
transcription. 
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Fie. 4. HSV1-TK expression in U-TK cells and ACV effect on HIV replication. (A) HSV1-TK transcripts of various U-TK clones were analyzed by 
RPA. (B) U-TK12 and U-TK16 cells were infected with HIV and cultured in the presence of ACV. Every 3-4  days, HIV antigens were measured in 
the culture supernatant by ELISA. 
In HUT-78 cells that constitutively express the HSV1- 
TK gene, ACV causes partial inhibition of HIV spread 
To further analyze the role of reverse transcription inhi- 
bition in the protection from HIV spreading of HSVl-TK- 
harboring cells by ACV, we investigated the efficiency of 
the protection in a cell line harboring a constitutively 
expressed HSV1-TK gene. We generated these cells 
(HUT-TKMLv) by infection of HUT-78 cells with recombi- 
nant defective retroviruses harboring an HSVl-TK gene 
under the transcriptional control of Moloney murine ]eu- 
kaemia regulatory sequences and a neomycin phospho- 
transferase gene. These cells were selected with G418 
and analyzed for sensitivity to ACV which was identical 
to HUT-TK cells (data not shown). Transcription from the 
Moloney LTR is not induced by HIV-1 Tat expression. 
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FIG. 5. Effect of ACV on HIV DNA synthesis in infected HUT-78 and HUT-TK cells. Phosphorimager quantification of HIV full-length unintegrated 
linear DNA in Hirt supernatants from HUT-78 or HUT-TK cells following a 6-hr ceculture with chronically infected H9 cells. The results are expressed 
in percentage of the amount of HIV unintegrated linear DNA measured in untreated cells, 
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When infected with HIV and cultured in the presence of 
increasing ACV concentrations, there is a significant and 
reproducible delay in HIV replication at 10 #M ACV, a 
dose at which HUT-TK cells are fully protected in the 
same experiments (Fig. 6). Therefore, the presence of 
basal HSV1-TK activity in HUT-TKMLv confers some anti- 
HIV inhibitory effects upon ACV, an effect that can be 
markedly amplified in cells harboring a Tat-inducible 
HSVl-TK gene. 
DISCUSSION 
We have developed a strategy for gene therapy of HIV 
infection based upon the destruction of HlV-infected cells 
that contain an HIV-inducible suicide gene. The efficacy 
of this approach should depend in large part upon the 
ability to gain appropriate control of the suicide gene 
expression. We reported that lymphoid cells harboring 
an HSV1-TK gene under the control of HIV regulatory 
sequences are protected from HIV spread by treatment 
of the cell culture with ACV (Caruso and Klatzmann, 
1992). The mechanism of this effect needs to be under- 
stood. It was not possible in those experiments to deter- 
mine hew much of the protective effect was due to the 
destruction of the initial population of infected cells and 
how much was due to the ability of ACV-TP to inhibit HIV 
reverse transcription. 
In this report, we show that both mechanisms contrib- 
ute to the protection of cells from HIV infection. There is 
a basal level of HSV1-TK transcription in uninfected HUT- 
TK or U-TK cells that is initiated at the HIV-LTR transcrip- 
tional start site. After HIV infection, HSV1 -TK transcription 
from the LTR start site is strongly induced, and therefore 
HSV1-TK expression is controlled by the HIV regulatory 
sequences. The basal expression of HSV1-TK is not 
harmful for HUT-TK cells in the presence of 10 #M ACV. 
In chronically infected HUT-TK cells, HSV1-TK mRNA ex- 
pression is transactivated 40-fold, and these cells are 
now killed at 10 #M ACV. The rate of their death was 
approximately 50% every 4 days, with most cells being 
killed by Day 15. This relatively slow rate of cell death is 
probably reflecting the increased doubling time of the 
chronically infected HUT-TK cells, since the mechanism 
of ACV-TP-mediated cell killing involves DNA chain termi- 
nation in replicating cells. 
The sensitivity to ACV-induced toxicity and the ability 
of a given cell line to generate ACV-TP correlate well. 
HUT-78 cells that do not express HSV1-TK very poorly 
metabolize ACV, and these cells tolerate an ACV concen- 
tration greater than 100 #M. In HUT-TK cells with basal 
expression of HSV1-TK, some ACV-TP is produced, and 
their sensitivity to ACV is increased 10-fold relative to 
HUT-78 cells. In chronically infected HUT-TKc~ with in- 
duced HSV-1 TK expression, much more ACV-TP is 
made, and the cells are now killed at 10 #M ACV (Fig. 
2A). Thus low levels of ACV-TP can be tolerated by a 
dividing cell, and the AOV-mediated toxicity for a given 
cell depends, both upon ACV concentration and the level 
of expression of HSV1-TK. in our experimental system, 
an ACV concentration that is tolerated by cells with basal 
expression of an HSV1-TK-HIV-inducible gene causes 
cell death in the presence of HIV infection, and selec- 
tively ablates the spread of HIV. 
inhibition of reverse transcription also contributes to 
the protection against HIV. Treatment of HUT-TK cells 
with ACV significantly reduces HIV DNA synthesis at 
short times after infection with a high m.o.i., although not 
as efficiently than AZT. This inhibition is much less potent 
in HUT-78 cells. It may be due to trace amount of ACV- 
TP present in HUT-78 cells or to a perturbation of the 
nucleotide pools required for efficient reverse transcrip- 
tion (Meyerhans et al., 1994; O'Brien et aL, 1994). This 
modest effect does net translate to the ability of ACV to 
measurably interfere with viral spread in HUT-78 (Fig. 6). 
In contrast, ACV does cause a significant inhibition of 
HIV spread in HUT-78 cells that contain a constitutively 
expressed HSV1-TK gene and at a concentration that 
does not kill these cells (Fig. 6). This effect is most proba- 
bly related to an ACV-TP-mediated inhibition of HIV re- 
verse transcription. 
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Recently, retroviral vectors that contain an HIV-induc- 
ible HSV1-TK gene have been constructed and shown 
to render transduced cells susceptible to cell killing by 
ganciclovir in the presence of Tat, but have not yet di- 
rectly demonstrated a protective effect from HIV infection 
(Brady etaL, 1994). These vectors were designed with the 
aim of specifically reducing HSV1-TK basal expression. 
Indeed, ganciclovir is very toxic for cells expressing low 
levels of HSV1-TK, while these cells tolerate well ACV. 
Our observations that inhibition of HIV reverse transcrip- 
tion with ACV may be a component of the protective effect 
against viral spread suggests that the optimal balance 
between basal and induced expression remains to be 
determined. 
This approach also protects monocytic cells, an im- 
portant reservoir of HIV infected cells, from further viral 
spread. Full arrest of HIV replication in the monocytic 
transfectants required a threefold higher concentration 
of ACV than in the lymphocytic ell line. This may be due 
to variation in the nucleoside pools between different 
cells, the kinetics of HIV replication and the extent of 
HSV1-TK transactivation. Finally, preliminary results indi- 
cate that AZT and ACV in combination are (at least) addi- 
tive in their ability to block HIV replication in HUT-TK and 
U-TK cells, and the efficacy of this approach may be 
further optimized by using combinations of nucleoside 
analogs. The vast clinical experience that has been accu- 
mulated with the nucleoside analogs is an important 
asset that can be exploited in the optimization of this 
therapeutic approach. 
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